Patents by Inventor Arthur M. Krieg
Arthur M. Krieg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7223741Abstract: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant.Type: GrantFiled: July 14, 2003Date of Patent: May 29, 2007Assignee: University of Iowa Research FoundationInventor: Arthur M. Krieg
-
Patent number: 6949520Abstract: Methods and compositions are provided for extending the clinical utility of IFN-? in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-? treatment and reduce IFN-? treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.Type: GrantFiled: September 27, 2000Date of Patent: September 27, 2005Assignees: Coley Pharmaceutical Group, Inc., University of Iowa Research Foundation, Coley Pharmaceutical GmbHInventors: Gunther Hartmann, Robert L. Bratzler, Arthur M. Krieg
-
Patent number: 6821957Abstract: The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immununostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.Type: GrantFiled: September 26, 2001Date of Patent: November 23, 2004Assignee: University of Iowa Research FoundationInventors: Arthur M. Krieg, Heather L. Davis, Tong Wu, Schorr Joachim
-
Publication number: 20040229835Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: June 24, 2004Publication date: November 18, 2004Applicants: The University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040198680Abstract: The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.Type: ApplicationFiled: July 3, 2003Publication date: October 7, 2004Applicant: Coley Pharmaceutical Group, Inc.Inventor: Arthur M. Krieg
-
Publication number: 20040198688Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: April 2, 2004Publication date: October 7, 2004Applicants: The University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., U.S.A., as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040186067Abstract: The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immunostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.Type: ApplicationFiled: September 26, 2001Publication date: September 23, 2004Inventors: Arthur M. Krieg, Heather L. Davis, Tong Wu, Joachim Schorr
-
Publication number: 20040181045Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: September 16, 2004Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040171571Abstract: The invention relates to a class of CpG immunostimulatory oligonucleotides containing a 5′TCG motif or a CG at or near the 5′ end that are useful for stimulating an immune response.Type: ApplicationFiled: December 11, 2003Publication date: September 2, 2004Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Marion Jurk, Jorg Vollmer, Eugen Uhlmann
-
Publication number: 20040171150Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: September 2, 2004Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040167089Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: January 30, 2004Publication date: August 26, 2004Applicants: The University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The USA as represented by the Secretary, Dept. of Health and Human ServicesInventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040162262Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: August 19, 2004Applicants: University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040162258Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: January 30, 2004Publication date: August 19, 2004Applicants: University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The USA as represented by the Secretary, Dept. of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040152656Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: August 5, 2004Applicants: University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040152657Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: August 5, 2004Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040152649Abstract: The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.Type: ApplicationFiled: July 3, 2003Publication date: August 5, 2004Applicant: Coley Pharmaceutical Group, Inc.Inventor: Arthur M. Krieg
-
Publication number: 20040147468Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: October 3, 2003Publication date: July 29, 2004Inventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040142469Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: July 22, 2004Applicants: University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040143112Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: October 21, 2003Publication date: July 22, 2004Inventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040132685Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: December 22, 2003Publication date: July 8, 2004Applicant: The University of Iowa Research FoundationInventors: Arthur M. Krieg, Joel Kline